MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies

참고문헌 (110)

1. Ambros, V., "The functions of animal microRNAs", Nature, 431, pp.350~355 (2004)
2. Wightman, B., "Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans", Cell, 75, pp.855~862 (1993)
3. Lee, R. C., "The C. elegans heterochronic gene lin-4encodes small RNAs with antisense complementarity to lin-14", Cell, 75, pp.843~854 (1993)
4. Kim, T., "MicroRNA and ER stress in cancer", Semin. Cancer Biol, 75, pp.3~14 (2021)
5. Miyoshi, K., "Many ways to generate microRNA-like small RNAs : non-canonical pathways for microRNA production", Mol. Genet. Genom, 284, pp.95~103 (2010)
6. Jame-Chenarboo, F., "High-Throughput Analysis Reveals miRNA Upregulating α-2, 6-Sialic Acid through Direct miRNA–mRNA Interactions", ACS Cent. Sci, 8, pp.1527~1536 (2022)
7. Laitinen, P., "Nuclear microRNA-466c regulates Vegfa expression in response to hypoxia", PLOS ONE, 17, pp.e0265948~ (2022)
8. Calin, G. A., "Nonlinear partial differential equations and applications : Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia", Proc. Natl Acad. Sci, 99, pp.15524~15529 (2002)
9. He, L., "A microRNA component of the p53 tumour suppressor network", Nature, 447, pp.1130~1134 (2007)
10. Raver-Shapira, N., "Transcriptional Activation of miR-34a Contributes to p53-Mediated Apoptosis", Mol. Cell, 26, pp.731~743 (2007)
11. Kim, T., "p53 regulates epithelial–mesenchymal transition through micro-RNAs targeting ZEB1 and ZEB2", J. Exp. Med, 208, pp.875~883 (2011)
12. O’Donnell, K. A., "c-Mycregulated microRNAs modulate E2F1 expression", Nature, 435, pp.839~843 (2005)
13. Calin, G. A., "MicroRNA signatures in human cancers", Nat. Rev. Cancer, 6, pp.857~866 (2006)
14. Li, Y., "MicroRNAs in Common Human Diseases", Genom. Proteom. Bioinforma, 10, pp.246~253 (2012)
15. Chakraborty, C., "Therapeutic advances of miRNAs : A preclinical and clinical update", J. Adv. Res, 28, pp.127~138 (2021)
16. Gallant-Behm, C. L., "A synthetic microRNA-92a inhibitor(MRG-110)accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds", Wound Repair Regener, 26, pp.311~323 (2018)
17. Doebele, C., "Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells", Blood, 115, pp.4944~4950 (2010)
18. Abplanalp, W. T., "Efficiency and Target Derepression of Anti-miR-92a : Results of a First in Human Study", Nucleic Acid Ther, 30, pp.335~345 (2020)
19. Lee, T. -H., "MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection", J. Med. Virol, 87, pp.1722~1726 (2015)
20. Ottosen, S., "In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122", Antimicrobial Agents Chemother, 59, pp.599~608 (2014)
21. Patel, V., "miR-17~92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease", Proc. Natl Acad. Sci, 110, pp.10765~10770 (2013)
22. Lee, E. C., "Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease", Nat. Commun, 10, pp.4148~ (2019)
23. Bais, T., "Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease", Drugs, 82, pp.1095~1115 (2022)
24. Hanna, J., "The Potential for microRNA Therapeutics and Clinical Research", Front. Genet, 10, pp.478~ (2019)
25. Chioccioli, M., "A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis", eBioMedicine, 85, pp.104304~ (2022)
26. Sung, J. J. Y., "Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication", Gut, 69, pp.1572~1580 (2020)
27. Ji, J., "Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy", Int. J. Mol. Sci, 21, pp.1136~ (2020)
28. Russo, F., "Probiotics against neoplastic transformation of gastric mucosa : Effects on cell proliferation and polyamine metabolism", World J. Gastroenterol, 20, pp.13258~ (2014)
29. Yang, J., "Role of the Gastric Microbiome in Gastric Cancer : From Carcinogenesis to Treatment", Front. Microbiol, 12, pp.641322~ (2021)
30. Bakhti, S. Z., "Interplay and cooperation of Helicobacter pylori and gut microbiota in gastric carcinogenesis", BMC Microbiol, 21, pp.258~ (2021)
31. Penumetcha, S. S., "The Efficacy of Probiotics in the Management of Helicobacter Pylori : A Systematic Review", Cureus, 13, pp.e20483~ (2021)
32. Yue, H., "MIR-519d suppresses the gastric cancer epithelial-mesenchymal transition via Twist1 and inhibits Wnt", β-catenin signaling pathway, 2017, pp.9, 3654~3664
33. Yanaka, Y., "miR-544a induces epithelial–mesenchymal transition through the activation of WNT signaling pathway in gastric cancer", Carcinogenesis, 36, pp.1363~1371 (2015)
34. Wu, K., "miR-483-5p promotes growth, invasion and self-renewal of gastric cancer stem cells by Wnt", β-catenin signaling, 2016, pp.14, 3421~3428
35. Fan, D., "Upregulation of miR-501-5p activates the wnt", β-catenin signaling pathway and enhances stem cell-like phenotype in gastric cancer, 2016, pp.35, 177~
36. Cheng, C., "Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K", Akt and Wnt, Int. J. Biol. Macromol, pp.2018, 107[DOI]
37. Sun, G. -L., "miR-324-3p promotes gastric cancer development by activating Smad4-mediated Wnt", beta-catenin signaling pathway, 2017, pp.53, 725~739
38. Huang, J., "miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt", β-catenin, BMC Cancer, pp.2017, 17[DOI]
39. Fang, Z., "miR‑381 and miR‑489 suppress cell proliferation and invasion by targeting CUL4B via the Wnt", β‑catenin pathway in gastric cancer, 2018, pp.54, 733~743
40. Xian, X., "miR-23b-3p and miR-130a-5p affect cell growth, migration and invasion by targeting CB1R via the Wnt", β-catenin signaling pathway in gastric carcinoma, 2018, pp.11, 7503~7512
41. Peng, Y., "Inhibition of miR‑194 suppresses the Wnt", β‑catenin signalling pathway in gastric cancer, 2018, pp.40, 3323~3334
42. Song, H., "BRD4 promotes the stemness of gastric cancer cells via attenuating miR-216a-3p-mediated inhibition of Wnt", β-catenin signaling, 2019, pp.852, 189~197
43. Li, Y., "Aberrantly expressed miR-188-5p promotes gastric cancer metastasis by activating Wnt", β-catenin signaling, 2019, pp.19, 505~
44. Yuan, J., "MIR17HG-miR-18a", 19a axis, regulated by interferon regulatory factor-1, promotes gastric cancer metastasis via Wnt, Cell Death Dis, pp.2019, 10[DOI]
45. Li, W., "MiR-503 suppresses cell proliferation and invasion of gastric cancer by targeting HMGA2 and inactivating WNT signaling pathway", Cancer Cell Int, 19, pp.164~ (2019)
46. Jiang, K., "Long non-coding RNA TOB1-AS1modulates cell proliferation, apoptosis, migration and invasion through miR-23a", NEU1 axis via Wnt, Eur. Rev. Med. Pharmacol. Sci, pp.2019, 23[DOI]
47. Zheng, J., "Hypoxia Activates SOX5", Wnt, Technol. Cancer Res. Treat, pp.2020, 19[DOI]
48. Ma, B., "Effects of miR-330-3p on Invasion, Migration and EMT of Gastric Cancer Cells by Targeting PRRX1-Mediated Wnt", β-Catenin Signaling Pathway, 2020, pp.13, 3411~3423
49. Zhou, W., "miR-6838-5p Affects Cell Growth, Migration, and Invasion by Targeting GPRIN3 via the Wnt", β-Catenin Signaling Pathway in Gastric Cancer, 2020, pp.87, 327~337
50. Guan, B., "LncRNA NCK1-AS1 exerts oncogenic property in gastric cancer by targeting the miR-22-3p", BCL9 axis to activate the Wnt, Environ. Toxicol, pp.2021, 36[DOI]
51. Iorio, M. V., "MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer", Eur. J. Cancer, 44, pp.2753~2759 (2008)
52. To, K. K, "MicroRNA : a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy", J. Biomed. Sci, 20, pp.99~ (2013)
53. Robertson, N. M., "The role of microRNA in resistance to breast cancer therapy", Wiley Interdiscip. Rev.: RNA, 5, pp.823~833 (2014)
54. Dehghanzadeh, R., "MicroRNA-induced drug resistance in gastric cancer", Biomed. Pharmacother, 74, pp.191~199 (2015)
55. Mihanfar, A., "MicroRNA-mediated drug resistance in ovarian cancer", J. Cell. Physiol, 234, pp.3180~3191 (2017)
56. Jiao, X., "microRNA : The Impact on Cancer Stemness and Therapeutic Resistance", Cells, 9, pp.8~ (2020)
57. Guo, Q., "The Role of Exosomal microRNA in Cancer Drug Resistance", Front. Oncol, 10, pp.472~ (2020)
58. Smolarz, B., "miRNAs in Cancer(Review of Literature)", Int. J. Mol. Sci, 23, pp.2805~ (2022)
59. Lu, X., "Plasmon-enhanced biosensors for microRNA analysis and cancer diagnosis", Biosens. Bioelectron, 203, pp.114041~ (2022)
60. Ma, M., "The Role and Mechanism of microRNA-1224 in Human Cancer", Front. Oncol, 12, pp.858892~ (2022)
61. Zhenshun Cheng, "MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2", Experimental and Molecular Medicine, 46, pp.1~9 (2014), 생화학분자생물학회
62. Fang Wang, "miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy", Experimental and Molecular Medicine, 47, pp.1~8 (2015), 생화학분자생물학회
63. Radanova, M., "Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis", Biomedicines, 10, pp.156~ (2022)
64. Liao, Y., "A-to-I RNA editing as a tuner of noncoding RNAs in cancer", Cancer Lett, 494, pp.88~93 (2020)
65. Kim Hyung Seok, "ADAR1-dependent miR-3144-3p editing simultaneously induces MSI2 expression and suppresses SLC38A4 expression in liver cancer", Experimental and Molecular Medicine, 55, pp.95~107 (2023), 생화학분자생물학회[DOI]
66. Meyer Kate, D., "Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons", Cell, 149, pp.1635~1646 (2012)
67. Pan Xiaoping, "METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner", Experimental and Molecular Medicine, 53, pp.1~12 (2021), 생화학분자생물학회[DOI]
68. Daoyang Zhou, "DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells", Experimental and Molecular Medicine, 47, pp.1~11 (2015), 생화학분자생물학회
69. Misso, G., "Mir-34 : A New Weapon Against Cancer? Mol", Ther. -Nucleic Acids, 3, pp.e194~ (2014)
70. Rokavec, M., "The p53", miR-34 axis in development and disease, 2014, pp.6, 214~230
71. Ling, H., "MicroRNAs and other non-coding RNAs as targets for anticancer drug development", Nat. Rev. Drug Discov, 12, pp.847~865 (2013)
72. Peltier, H. J., "Effects of MRX34, a liposomal miR-34 mimic, on target gene expression in human white blood cells (hWBCs): qRT-PCR results from a first-in-human trial of microRNA cancer therapy", Ann. Oncol, 27, pp.vi531~ (2016)
73. Hong, D. S., "Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours", Br. J. Cancer, 122, pp.1630~1637 (2020)
74. Croce, C. M., "Causes and consequences of microRNA dysregulation in cancer", Nat. Rev. Genet, 10, pp.704~714 (2009)
75. Dong, J. -T., "Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer", Prostate, 49, pp.166~171 (2001)
76. Cimmino, A., "miR-15 and miR-16 induce apoptosis by targeting BCL2", Proc. Natl Acad. Sci, 102, pp.13944~13949 (2005)
77. Ramaiah, M. J., "Functions and epigenetic aspects of miR-15", 16 : Possible future cancer therapeutics, 2018, pp.12, 149~164
78. van Zandwijk, N., "Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma : a first-in-man, phase 1, open-label, dose-escalation study", Lancet Oncol, 18, pp.1386~1396 (2017)
79. Kalkusova, K., "The Role of miR-155 in Antitumor Immunity", Cancers, 14, pp.5414~ (2022)
80. Bayraktar, R., "miR-155 in cancer drug resistance and as target for miRNA-based therapeutics", Cancer Metastasis Rev, 37, pp.33~44 (2017)
81. Witten, L, "miR-155 as a novel clinical target for hematological malignancies", Carcinogenesis, 41, pp.2~7 (2019)
82. Costinean, S., "Pre-B cell proliferation and lymphoblastic leukemia", highgrade lymphoma in Eμ-miR155 transgenic mice, 2006, pp.103, 7024~7029
83. Anastasiadou, E., "Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo", Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res, 27, pp.1139~1149 (2021)
84. Seto, A. G., "Cobomarsen, an oligonucleotide inhibitor of miR-155, coordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma", Br. J. Haematol, 183, pp.428~444 (2018)
85. Khordadmehr, M., "miR-193 : A new weapon against cancer", J. Cell. Physiol, 234, pp.16861~16872 (2019)
86. Ovcharenko, D., "Genome-Scale MicroRNA and Small Interfering RNA Screens Identify Small RNA Modulators of TRAIL-Induced Apoptosis Pathway", Cancer Res, 67, pp.10782~10788 (2007)
87. Nakano, H., "Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells", Int. J. Oncol, 42, pp.1875~1882 (2013)
88. Wang, J., "MicroRNA-193 Pro-Proliferation Effects for Bone Mesenchymal Stem Cells After Low-Level Laser Irradiation Treatment Through Inhibitor of Growth Family, Member 5", Stem Cells Dev, 21, pp.2508~2519 (2012)
89. Telford, B. J., "Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology", Oncotarget, 12, pp.422~439 (2021)
90. van den Bosch, M. T. J., "Transcriptome-wide analysis reveals insight into tumor suppressor functions of 1B3, a novel synthetic miR-193a-3p mimic", Mol. Ther. -Nucleic Acids, 23, pp.1161~1171 (2021)
91. Tehler, D., "The miR-10 microRNA precursor family", RNA Biol, 8, pp.728~734 (2011)
92. Ma, L., "Tumour invasion and metastasis initiated by microRNA-10b in breast cancer", Nature, 449, pp.682~688 (2007)
93. Ma, L., "Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model", Nat. Biotechnol, 28, pp.341~347 (2010)
94. Yoo, B., "Design of Nanodrugs for miRNA Targeting in Tumor Cells", J. Biomed. Nanotechnol, 10, pp.1114~1122 (2014)
95. Yigit, M. V., "Magnetic Nanoparticles for Cancer Diagnosis and Therapy", Pharm. Res, 29, pp.1180~1188 (2012)
96. Weissleder, R., "Polyclonal human immunoglobulin G labeled with polymeric iron oxide : antibody MR imaging", Radiology, 181, pp.245~249 (1991)
97. Sheedy, P., "The fundamental role of miR-10b in metastatic cancer", Am. J. Cancer Res, 8, pp.1674~1688 (2018)
98. Liang, L., "A narrative review of microRNA therapeutics : understanding the future of microRNA research", Precis. Cancer Med, 4, pp.33~33 (2021)
99. Romano, G., "microRNAs as Novel Therapeutics in Cancer", Cancers, 13, pp.1526~ (2021)
100. "Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme" (2017)[URL]
101. Quirico, L., "The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies", Cancer Drug Resist, 3, pp.117~139 (2020)
102. Zhang, C., "Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021", Int. J. Mol. Sci, 23, pp.11389~ (2022)
103. Mirahmadi, Y., "MicroRNAs as Biomarkers for Early Diagnosis, Prognosis, and Therapeutic Targeting of Ovarian Cancer", J. Oncol, 2021, pp.1~25 (2021)
104. Zografos, E., "Prognostic role of microRNAs in breast cancer : a systematic review", Oncotarget, 10, pp.7156~7178 (2019)
105. Ji, L., "Regulation of small RNA stability : methylation and beyond", Cell Res, 22, pp.624~636 (2012)
106. Kai, Z. S., "MicroRNA assassins : factors that regulate the disappearance of miRNAs", Nat. Struct. Mol. Biol, 17, pp.5~10 (2010)
107. O’Brien, J., "Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation", Front. Endocrinol, 9, pp.402~ (2018)
108. Mitchell, P. S., "Circulating microRNAs as stable blood-based markers for cancer detection", Proc. Natl Acad. Sci, 105, pp.10513~10518 (2008)
109. Yang, N., "MicroRNAs : Pleiotropic Regulators in the Tumor Microenvironment", Front. Immunol, 9, pp.2491~ (2018)
110. Hanahan, D., "Hallmarks of cancer: the next Generation", Cell, 144, pp.646~674 (2011)

관련 논문AI추천